What Akebia Therapeutics, Inc. told the SEC could break it.

Akebia's U.S. Vafseo commercialization depends on a highly concentrated dialysis-provider channel: a small number of large dialysis organizations treat the bulk of patients (the largest treat ~82% of the total dialysis population), treatment is driven by protocols those organizations implement network-wide, and Akebia had commercial-supply contracts with dialysis organizations caring for nearly 100% of dialysis patients; loss or unfavorable renewal of a major dialysis-organization/GPO contract would materially reduce Vafseo demand.

“Prior to the availability of Vafseo in the U.S. in January 2025, we had contracts in place with dialysis organizations caring for nearly 100% of dialysis patients.”

Akebia owns no manufacturing or distribution facilities and relies entirely on third parties — in many cases a single supplier or distributor: it uses single-source suppliers for both drug substance and drug product for Auryxia (including its authorized generic) with no readily available alternative, an exclusive third-party logistics provider for commercial sales of Auryxia and Vafseo, and all Vafseo drug substance/product is manufactured in China by WuXi STA (a WuXi AppTec subsidiary); loss of, or a failure by, any of these single sources could disrupt supply and impair commercialization.

“We currently rely on single source suppliers for each of drug substance and drug product for Auryxia, including for our authorized generic, and commercial supply from other suppliers is not readily available, and our exclusive 3PL for commercial sales of Auryxia and Vafseo.”

Akebia carries meaningful secured debt and royalty obligations: its BlackRock Term Loan Facility is secured by substantially all existing and after-acquired assets and requires it to maintain at least $15.0 million of cash (or meet a revenue test) each month and bars dividends without lender consent, and it must repay CSL Vifor's Working Capital Fund through quarterly tiered royalty payments of 8%-14% of U.S. Vafseo net sales (up to $40 million through May 2028) plus other royalty-interest financing; covenant breaches, rising rates or weak Vafseo sales could pressure liquidity.

“All obligations under the Term Loan Facility are secured by substantially all of our existing and after-acquired assets. The BlackRock Credit Agreement requires us to either (i) maintain cash and cash equivalents, measured as of the last day of each fiscal month, greater than or equal to $15.0 million”

Akebia manufactures all Vafseo in China (WuXi STA) and Auryxia/Vafseo drug product in Canada (Patheon), so escalating U.S.-China/Canada trade tensions and tariffs (2025 reciprocal tariffs, retaliatory measures, and the uncertain landscape after the February 2026 Supreme Court ruling that IEEPA does not authorize the tariffs) could raise its manufacturing costs and disrupt cross-border supply of raw materials and finished product; it is also subject to EU GDPR data-privacy rules and to drug pricing/reimbursement (including Medicare/Medicare Advantage and IRA) dynamics central to product uptake.

“Many of our manufacturers and suppliers for Auryxia and Vafseo are located in China, Europe and Canada, and we may continue to rely on foreign CMOs in the future.”